North China Pharmaceutical controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
North China Pharmaceutical placed on violation list over ibuprofen supply shortage in centralized procurement
In 2021, ibuprofen sustained-release capsules won by North China Pharmaceutical in centralized procurement were undersupplied in Shandong; the relevant procurement agency initiated substitute supply procedures, and the company was placed on the centralized procurement violation list and restricted for a certain period from applying for national drug centralized procurement. This incident involved supply performance, not a failure in drug quality sampling inspection.
2021
Huabei Pharmaceutical barred from national drug procurement participation
Ban or restriction
The National Drug Centralized Procurement Office placed Huabei Pharmaceutical on its violation list and cancelled its eligibility to apply for national centralized drug procurement from August 11, 2021 through May 10, 2022. The office said the company failed to supply the agreed quantity of ibuprofen sustained-release capsules in Shandong and had requested to give up its selected status.
Source excerpt
由于该公司在第三批国家组织药品集采中选的布洛芬缓释胶囊未能在山东省按协议供应约定采购量，经多次约谈协商，供应情况仍未改善，该企业于2021年8月11日提出放弃中选资格。
国家组织药品联合采购办公室(以下简称“联采办”)将华北制药纳入“违规名单”，取消其自2021年8月11日至2022年5月10日参与国家组织药品集中采购活动的申报资格。